Summary
UCB, a Belgian pharmaceutical company, has announced a $2.2 billion deal to acquire Candid Therapeutics, a startup focused on developing bispecific antibodies for autoimmune diseases. This acquisition adds to the growing interest in immune medicines that can “reset” the immune system instead of broadly suppressing it, with several other pharmaceutical companies also making moves in this area.
Access impact
The acquisition of Candid by UCB has significant pricing, reimbursement, and HTA implications. The company’s pipeline of bispecific drugs, particularly cizutamig, has the potential to be a “transformative asset” for immune diseases and may become a “best-in-class” T cell engager. This could lead to a positive market access outlook for UCB’s investments in this area.
Top-3 domain lens
Clinical Effectiveness
Cizutamig, a dual-targeting therapy acquired by UCB in the deal, has shown promising results in eliminating harmful cells while limiting dangerous immune responses. It has been studied in over 100 patients with multiple myeloma and autoimmune diseases, and is currently being evaluated for use in over 10 autoimmune indications.
Safety and Tolerability
UCB noted that cizutamig is designed to limit the onset of cytokine release syndrome, a dangerous immune response associated with T cell engagers. This could be a key factor in ensuring the drug’s safety and tolerability, making it more likely to be accepted by payers and HTA bodies.
Evidence Quality and Robustness
Cizutamig has been studied in a significant number of patients and is currently being evaluated in multiple clinical trials for various indications. This data could support its effectiveness and robustness, making it more likely to receive positive reimbursement decisions.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug.
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/ucb-candid-deal-bispecifics-t-cell-engagers-autoimmune-china/819155/